Small molecule Drugs
Propargylcysteine (ZYZ-802):
A novel compound synthesized and extracted from garlic, a natural source product, capable of alleviating inflammatory responses in rheumatoid arthritis by modulating the Nrf2-ARE signaling pathway.
Propargylcysteine (ZYZ-802) Development Milestones
Target Hypothesis Proposed
Professor Zhu Yizhun led the drug development team in first proposing the CSE (cystathionine γ-lyase) target as a novel therapeutic approach for rheumatoid arthritis in ELSEVIER, a globally renowned academic journal.
Mechanism Published in Prestigious Journal
The novel mechanism of propargylcysteine (ZYZ-802) and JMJD3 inhibitors for rheumatoid arthritis treatment was published in a Nature sub-journal.
Science Recognition
CSE (cystathionine γ-lyase) was selected by Science as one of the top 10 global drug targets.
Preclinical Submission
Propargylcysteine (ZYZ-802) completed preclinical research submission as a first-in-class new drug.
Selected Indications Under Investigation
Rheumatoid Arthritis
Alzheimer’s Disease
Myocardial Injury
Infectious Diarrhea
Diabetic Foot Wound Repair
and Skin Regeneration
Intellectual Property
with 1 application pending